AVANT CEO to Present at the Needham & Company Biotechnology Conference.Business Editors/Health/Medical Writers BIOWIRE2K NEEDHAM, Mass.--(BUSINESS WIRE)--May 29, 2003 AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Dr. Una S. Ryan, President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will present at the Needham & Company Second Annual Biotechnology Conference at the New York Palace
New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. on Friday, June 6th at 10:30am, ET. A live webcast of the 30-minute presentation, together with a read-only copy of the presentation slides in Adobe Acrobat (.pdf) format, will be available online via the Investor Information area of AVANT's website at http://www.avantimmune.com and at http://www.twst.com/econf/mm/needham5/avan.html. An archive of the webcast will be available via AVANT's website for 60 days following the event. AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to prevent and treat disease. The company is developing a broad portfolio of vaccines addressing a wide range of applications including bacterial and viral diseases viral diseases Diseases caused by viruses. Long-term immunity usually follows viral childhood diseases (see chickenpox). The common cold recurs into adulthood because many different viruses cause its symptoms, and immunity against one does not protect against others. , chronic human disease, biodefense and food safety. These include single-dose, oral vaccines that protect against important disease-causing agents and a novel, proprietary vaccine candidate for cholesterol management. AVANT's goal is to demonstrate proof-of-concept for its products before leveraging their value through partnerships. Current collaborations encompass the development of an oral human rotavirus rotavirus /ro·ta·vi·rus/ (ro´tah-vi?rus) any member of the genus Rotavirus. ro´taviral Rotavirus /Ro·ta·vi·rus/ (ro´tah-vi?rus vaccine, vaccines to combat threats of biological warfare biological warfare, employment in war of microorganisms to injure or destroy people, animals, or crops; also called germ or bacteriological warfare. Limited attempts have been made in the past to spread disease among the enemy; e.g. , and vaccines addressed to human food safety and animal health. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: http://www.avantimmune.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion